San Francisco, CANCT04540107Now EnrollingIRB Ready

Recurrent World Health Organization (WHO) Grade II Glioma Clinical Trial in San Francisco, CA

Access cutting-edge recurrent world health organization (who) grade ii glioma treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by Susan Chang

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access recurrent world health organization (who) grade ii glioma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related recurrent world health organization (who) grade ii glioma treatment provided free

Apply for This San Francisco Location

Check if you qualify for this recurrent world health organization (who) grade ii glioma clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Recurrent World Health Organization (WHO) Grade II Glioma Study in San Francisco

This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.

Sponsor: Susan Chang

Who Can Participate

Inclusion Criteria

For patients in cohort 1: histologically proven lower grade glioma who are being followed with surveillance scans
For patients in cohort 2: histologically proven glioma who are scheduled for treatment due to suspected residual or recurrent tumor
Patients with a life expectancy \> 12 weeks
Patients must have a Karnofsky performance status of \>= 60
Patients must have adequate renal function (creatinine \< 1.5 mg/dL) before imaging. These tests must be performed within 60 days prior to the hyperpolarized imaging scan.
Patients must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the patient's ability to participate in this study or any disease that will obscure toxicity or dangerously impact response to the imaging agent.
Patients must not have New York Heart Association (NYHA) grade II or greater congestive heart failure
Patients must not have history of myocardial infarction or unstable angina within 12 months prior to study enrollment
This study was designed to include women and minorities, but was not designed to measure differences of intervention effects. Males and females will be recruited with no preference to gender. Minorities will actively be recruited to participate. No

Exclusion Criteria

to this study will be based on race
Patients must sign an informed consent indicating that they are aware of the investigational nature of this study. Patients must sign an authorization for the release of their protected health information
Patients may not be known to be human immunodeficiency virus (HIV)-positive. HIV testing is not required for study participation
Patients must not have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless they are in complete remission and have been off all therapy for that disease for a minimum of 3 years
Patients must not be pregnant or breast-feeding. Women of childbearing potential are required to obtain a negative pregnancy test within 14 days of hyperpolarized imaging scan. Effective contraception (men and women) must be used in subjects of child-bearing potential Exclusion Criteria:
Subjects will be excluded from participating in this study if they are unable to comply with study and/or follow-up procedures

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT04540107) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Recurrent World Health Organization (WHO) Grade II Glioma Treatment Options in San Francisco, CA

If you're searching for recurrent world health organization (who) grade ii glioma treatment options in San Francisco, CA, this clinical trial (NCT04540107) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced recurrent world health organization (who) grade ii glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all recurrent world health organization (who) grade ii glioma clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in San Francisco, CA

See all brain cancer clinical trials recruiting in San Francisco — not just this study.

Browse Brain Cancer Trials in San Francisco →

Browse More Trials by Condition

Brain Cancer TrialsAlzheimers Disease TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA